Despite improvements in the management of liver cancer, the survival rate for individuals with hepatocellular carcinoma (HCC) remains dismal. The survival benefit of systemic chemotherapy for the treatment of liver cancer is only marginal. Although the reasons for treatment failure are multifactorial, intrinsic resistance to chemotherapy plays a primary role. Here, we analyzed the expression of 377 multidrug resistance-associated genes in two independent cohorts of patients with advanced hepatocellular carcinoma, with the aim of finding ways to improve survival in this poor-prognosis cancer. Taqman-based qPCR revealed a 45-gene signature that predicts overall survival (OS) in patients with HCC. Using the Connectivity Map Tool, we were able to identify drugs that converted the gene expression profiles of HCC cell lines from ones matching patients with poor OS to profiles associated with good OS. We found three compounds that convert the gene expression profiles of three HCC cell lines to gene expression profiles associated with good OS. These compounds increase histone acetylation, which correlates with the synergistic sensitization of those multidrug-resistant tumor cells to conventional chemotherapeutic agents including cisplatin, sorafenib and 5-fluorouracil. Our results indicate that it is possible to modulate gene expression profiles in HCC cell lines to those associated with better outcome.
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Introduction
Liver cancer is the third most common cancer in the world, causing approximately 745,000 deaths per year (Ferlay et al., 2015) . Hepatocellular carcinoma (HCC) is by far the most prevalent type, accounting for approximately 80 to 85% of primary liver cancer cases (Singal and El-Serag, 2015) , whereas cholangiocarcinoma (Ghouri et al., 2015) and fibrolamellar carcinoma (Cornella et al., 2015; Lim et al., 2014 ) occur only at a frequency of ~14% and ~1%, respectively. The epidemiology of HCC is well known, and in the vast majority of cases, it arises as a consequence of underlying liver disease, usually a viral hepatitis (Singal and El-Serag, 2015) .
In the case of hepatitis B, integration of the viral DNA into the hepatocyte genome results in loss of chromosomal stability, deregulation of tumor suppressor genes and activation of protooncogenes, eventually leading to the development of HCC (Su et al., 2014) .
Patients with early stage tumors undergo either surgical resection or liver transplantation if their HCC meets the so-called Milan criteria (Mazzaferro et al., 1996; Waller et al., 2015) . When the patients are not suitable for surgery, local ablation including radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) is standard treatment. TACE, transcatheter arterial chemoembolization, is recommended for patients with intermediate stage HCC (EASL-EORTC, 2012; Villanueva et al., 2013) . With the exception of sorafenib, a multi-tyrosine kinase inhibitor for which a survival benefit of three months was demonstrated, no effective systemic therapy exists for patients with advanced HCC (Llovet et al., 2008; . Although sorafenib is now established as the first line of therapy for advanced HCC, it was shown to be a substrate of ABCB1 and ABCG2, two major ABC transporters involved in multidrug resistance (MDR) and expressed in hepatocytes and hepatomas (Lagas et al., 2010; Tang et al., 2013) .
Comprehensive molecular profiling contributed to substantial improvement in our knowledge of This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on December 14, 2015 as DOI: 10.1124 at ASPET Journals on September 30, 2017 molpharm.aspetjournals.org Downloaded from the biology of liver cancer and provide a road map to facilitate the development of targeted therapies (Andersen and Thorgeirsson, 2012; Bruix et al., 2015; Pinyol et al., 2014; Simon et al., 2015) . Beside proof-of-concept trial testing signaling pathway inhibitors or biomarker-based trial enrichment for defining cancer subpopulations, there are still a need for unspecific drugs that target all patients (Llovet and Hernandez-Gea, 2014) .
Although the reasons for treatment failure are multifactorial, intrinsic resistance to chemotherapy plays a primary role. Here, the expression of multidrug resistance-associated genes were analyzed in two independent cohorts of patients with advanced hepatocellular carcinoma. We hypothesized that the Connectivity Map Tool might reveal compounds that reverse gene expression profile of cancers from patients with poor prognosis to that of cancers from patients who respond well to treatment (Lamb, 2007; Lamb et al., 2006; Zhang and Gant, 2008) . The ultimate aim is to find a new strategy to sensitize intrinsically multidrug-resistant cancer.
Materials and Methods
Tumor samples
Anonymized clinical samples of 38 hepatocellular carcinomas (HCCs) and 13 normal liver tissues were provided by Lee et al. (Lee et al., 2004) . The majority of the patients had an HBV background, but a few were HCV and alcoholic. All the samples originated from untreated primary resected tumors. Importantly, even though the majority of patients in this cohort were infected with HBV (which is also the common background for Chinese HCC patients), the cohort also includes HCV and alcoholic-related HCC cases, simulating a "true" clinical situation, MOL #101360 6 as patients with HCC are not normally a homogeneous group. Thirty-eight HCC samples were randomly selected to be reanalyzed among samples that were previously classified into two groups based on overall survival (Lee et al., 2004) . It was demonstrated by Lee et al. that although patients may originate from different ethnic groups, the cohort could still be considered homogeneous at the molecular level (Lee et al., 2006) . A total of seventeen normal liver samples were analyzed. Total RNA for N1-N4 was purchased commercially, N1 from Ambion (catalog number AM7960), N2 from Stratagene (catalog number 540017), N3 from Clontech (catalog number 636531), N4 from Biochain Institute (catalog number R1234149-50). RNA from N5-N17 was provided by the Laboratory of Experimental Carcinogenesis, National Cancer Institute.
TaqMan low density arrays (TLDAs)
Expression levels of 377 MDR-associated genes were measured in the above-mentioned samples using a custom-made Taqman Low Density Array (Applied Biosystems, Foster City, CA, USA), as previously reported (Calcagno et al., 2010) .
Normalization and filtering
The median expression of each sample was subtracted from all gene expression data for that sample. Two of the normal (N1, 2) and seven of the HCC samples (A1, 5, 8, 9, 11 and B16, 18) were analyzed in duplicate. For these 9 samples, the Pearson correlation between the duplicates was greater than 99%. These duplicates were averaged together. One of the genes (18S) was present as multiple probes. The expression data from the multiple probes for that gene were averaged together. Genes that were expressed in 10 or fewer samples were removed from the analysis.
Comparison of HCC and Normal Liver Samples
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Genes expressed differentially in HCC and normal samples were detected using the t-statistic.
The obtained p-values were adjusted for multiple comparisons using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) .
Comparison of samples from groups A and B
Unsupervised clustering (Average Linkage algorithm with 1-Pearson correlation as the distance) was done on the normalized, filtered data. Genes differentially expressed in groups A and B were detected using the t-statistic, with the p-values adjusted for multiple comparisons using the Benjamini-Hochberg method.
Validation of the 45 MDR-linked genes as a prognostic signature for poor overall survival
The clinical data of this cohort and the analysis of the gene expression profile was published by Andersen et al. (Andersen et al., 2010) . Analysis of survival data was performed by KaplanMeier using Mantal-Cox (log-rank) statistics (GraphPad.Prism v5).
Connectivity Map analysis
The up-and down-regulated genes found in 38 HCC samples that had an adjusted pvalue<0.05 in the TLDA data were used as input to the Connectivity Map online web tool (http://www.broadinstitute.org/science/projects/connectivity-map/connectivity-map).
Validation of the compounds highlighted by utilizing the connectivity map
All 20 cell lines were grown to 70-80% confluence. Twenty-four hours prior to RNA extraction using an RNeasy Micro kit (Qiagen, Valencia, CA), all cell lines were grown in DMEM/F12 (Invitrogen, Carlsbad, CA, USA). The RNA was prepared and profiled as previously mentioned in the section entitled "Validation of the 45 MDR-linked Genes as a Prognostic Signature for Poor Overall Survival." Integration was performed by z-transforming MOL #101360 8 each data set separately and the hierarchical clustering was performed using Cluster 3.0 and TreeView1.6.
Cell lines
HUH7, PLC and HEP3B, which clustered with samples from patients with poor overall survival, and HUH1, SNU182, and FOCUS clustering with samples from patients with better overall survival, were maintained in RPMI-1640 (Life Technologies, Invitrogen), supplemented with 10% FBS, 100 units of penicillin/streptomycin/mL at 37°C in 5% CO2 humidified air.
Cytotoxicity Assay to Determine Synergism of Added Drugs
To assess the synergistic effects of sorafenib, 6TG, 8-Aza, doxorubicin, apigenin, cisplatin, and 5-FU in combination, Huh7, Hep3B and PLC cells were each treated with a matrix of two different drugs with serial 1:2 dilutions from 100 µM to 0.001526 µM. Five thousand cells were seeded per well 16 h before addition of the drug combinations. According to the manufacturer's protocol, an MTT assay (Trevigen, Gaithersburg, MD) was performed to measure proliferation of cells at 72 h after drug addition. To evaluate sensitization effects, 20 µM of one drug was added for 24 h and removed. The second drug was added in a serial 1:2 dilution from 100 µM to 0.3906 µM and proliferation was measured at 72 h using the MTT assay. Three technical replicates were performed for the sensitization experiments. All additions of cells to 96-well plates, drug dilutions/additions and the MTT assay were carried out using a Hamilton Star Liquid Handler (Reno, Nevada). Synergy calculations were done using custom scripts on R (version 2.15.2).
Western-blot immunoassay
The following antibodies were used for a Western blot immunoassay: rabbit anti-acetyl histone H3 (1:1,000; Millipore, Billerica, MA, Cat. #06-599), rabbit anti-GAPDH (1:5,000; Cell MOL #101360 Signaling, Danvers, MA, Cat. #14C10). Horseradish peroxidase-linked secondary antibodies (1:10,000) were from DakoCytomation (Carpinteria, CA). Bands were visualized by chemiluminescence using X-ray film.
Silencing the histone acetyltranserase GCN5
A pGIPZ shRNA construct for stable knockdown of human GCN5 (KAT2A gene) was 
Results
Genes Differentially Expressed in HCC compared to Normal Liver Samples
We conducted a study on 17 normal liver samples and 38 HCC samples (generously provided by Thorgeirsson and colleagues (Lee et al., 2004; Lee et al., 2006) to compare the expression profile of 377 MDR-linked genes in normal and HCC samples. These genes, selected from the literature published over the last 30 years, were reported to have a role in multidrug resistance, mostly based on in vitro studies (Calcagno et al., 2010; . Our analysis revealed 103 genes that are differentially expressed in HCC compared to normal liver samples. Eightytwo genes have a false discovery rate (FDR) < 0.05 and p-value < 0.01, and 21 additional genes fulfill the less stringent criteria of FDR < 0.05 and p-value < 0.05 (Table 1 ). More precisely, 32 genes were found to be down-regulated in HCC compared to normal samples, while 71 were found to be up-regulated (Table 1) . Notably, 8 ABC transporters were found to be overexpressed in HCC. Many of these drug efflux transporters are important mediators of MDR (Gillet et al., 2007) . Within this group of 8 genes, the involvement of ABCC1, ABCC4, ABCC5 and ABCC10 in MDR has been well characterized (Gillet et al., 2007) . Our analysis also highlighted a cluster of genes involved in cell cycle regulation, including CDKN2A, CDK2 and 4, CCD42 and CCNE1. Moreover, the cell cycle checkpoints CHEK 1 and 2, and RAD1 were found to be over-expressed, as well as a large cluster of DNA repair genes including TOP2A, over-expressed 67-fold.
Four main groups of down-regulated genes were uncovered, including several ABC transporters, CYP450s, metallothioneins and solute carriers. None of the down-regulated ABC transporters were found to be involved in MDR except ABCC11, whereas several downregulated SLCs have been previously identified as drug transporters.
They include SLC21A8/SLCO1B3, SLC22A1/OCT1, SLC28A1/CNT1 and the copper transporter SLC31A1/CTR1, which also transports cisplatin, oxaliplatin and carboplatin (Huang, 2007; Kuo et al., 2007) .
Identification of an MDR-linked gene signature in a previously established group of poor overall survival patients
We characterized the differential MDR-linked gene expression of the 38 HCC samples, which were previously classified into two groups based on overall survival (Lee et al., 2004) . Group A consisted of 20 samples taken from Chinese patients with a poor overall survival, while Group B contained eleven samples taken from Chinese patients and 7 samples from Belgian patients. All
of the Group B patients demonstrated better overall survival.
Unsupervised clustering of all the genes expressed in more than 10 of the 38 samples yields distinct clusters for the HCC group A subtype (poor overall survival), the HCC group B subtype (good overall survival), and the normal samples, with few exceptions (Fig. 1A) . Supervised class comparisons highlighted 45 genes that are differentially expressed in Groups A and B (FDR<0.05), of which 29 were found to be up-regulated in patients with poor overall survival compared to patients with good overall survival, while 16 were found to be down-regulated (Table 2) . Perhaps the most striking finding is the up-regulation of 12 genes related to DNA repair, including cell cycle checkpoints CHEK1 and ATM, the regulators BRCA1 and 2, the double-strand break repair genes MRE11A, TOP2, RAD51, XRCC1, 2 and 5, and the single strand DNA repair gene TOP1. Three gene families were found to be down-regulated. They include five ABC transporter genes (ABCA6, B4, B11, C9 and G8), 4 CYP450s (CYP2A6, 2C8, 2C9 and 2C19) and three SLCs (SLC10A1, 22A1 and 28A1), which could be attributed to the This article has not been copyedited and formatted. The final version may differ from this version. 
Validation of the 45 MDR-linked genes as a prognostic signature for poor overall survival
We assessed the predictive power of the 45-gene signature identified as differentially expressed in A vs. B subtypes on an independent cohort of 53 HCCs obtained from Caucasian and Chinese patients (Andersen et al., 2010) . The gene expression profiling was performed using Illumina bead chips (Andersen et al., 2010) . We were interested in drugs that cause a change in gene expression that matches the gene expression change from group A to group B. From the up-and down-regulated genes obtained by TLDA that had an adjusted p-value <0.05, we found 4 drugs with high positive concordance, low p-value (p<0.001) and a low specificity score (specificity score<0.05). These drugs were 8-This article has not been copyedited and formatted. The final version may differ from this version. Table   S1 ).
To confirm our findings regarding these drugs, we performed an integrative clustering using the 45-gene signature in 20 HCC cell lines and the 53 HCC clinical samples of our validation set ( Fig. 2A) . Two HCC cell lines randomly selected, HUH7 and PLC, which clustered with samples from patients with poor overall survival, were treated for 72 hours with a sub-cytotoxic dose of each of the drugs individually except for compound 0175029-0000, which is unavailable. The data indicate that the treatment caused a change in the gene expression profile of the cell lines from that of poor overall survival to that of better overall survival (Fig. 2B ).
6-TG, 8-AZG and apigenin mediate increased acetylation of histone protein
We next hypothesized that the mechanism underlying the ability of these three compounds to change gene expression patterns might be associated with increased acetylation of histone protein. This was confirmed using an antibody directed against acetylated histone H3 in three HCC cell lines (HUH7, PLC, and HEP3B) treated for 6 hours with 10 M of either one of these drugs (Fig. 3A) . Optimization of the treatment (24 hours with 20 M) dramatically increased the effect observed, with a 3-to 6-fold increase in acetylated histone H3, and as much as a 13.5-fold increase when treated with depsipeptide as a positive control (Fig. 3B ).
To explore further the hypothesis that changes in gene expression patterns were due to increased histone H3 acetylation, we knocked down the expression of the major histone H3 acetyltransferase GCN5 (Fig. 4 , C-F). As hypothesized, drug treatment-induced histone acetylation decreased in the HUH7 and PLC cell lines when GCN5 was knocked down and to some extent in the HEP3B cell line, when treated with apigenin.
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Drug combinations show synergistic cytotoxicity
For each pair of drugs that were tested, we used combinations of varying concentrations to determine whether the combination of these drugs resulted in increased cytotoxicity and whether this effect was additive or synergistic. The combination of three drug pairs had a significant synergistic effect on all three HCC cell lines: 6-TG/Apigenin, doxorubicin/apigenin and sorafenib/Apigenin, and to some extent, 6-TG/5-FU (Fig. 4) , indicating that the changes we observed in gene expression patterns were also associated with increases in treatment efficacy over and above the toxicity of the drugs themselves.
Discussion
Using a TaqMan-based qRT-PCR array, we studied the expression profile of 377 MDRlinked genes and found a signature of 103 genes differentially expressed in normal liver cells and HCC. The MDR genotype consists of the up-regulation of several members of the ABCC family (known as MRPs), of genes involved in cell proliferation through regulation of the G1/S cell cycle transition, and of DNA repair genes. We also identified down-regulation of several solute carriers involved in platinum drug uptake, potentially resulting in a dramatic decrease in the cellular entry of this drug (Huang, 2007; Kuo et al., 2007) . The intrinsic expression of several additional ABC transporters known to efflux standard chemotherapeutics including ABCB1, ABCB4, ABCB11 and ABCG2, leaves limited treatment modalities to clinicians when coupled with the MDR-linked gene signature of HCC. Many of these ABC transporters have been shown to transport doxorubicin (Szakacs et al., 2006) . It should be noted that this poor prognosis MDR gene signature probably reflects a biological state of the HCC rather than being the sole cause of the poor prognosis, since the patients who were the source of the analyzed HCC samples were not treated with chemotherapeutic agents. However, the presence of these drug-resistance mechanisms in poor prognosis HCC makes it difficult to design chemotherapy that might be effective against these cancers. On the other hand, this 103-gene signature not only confirms the expression of known markers of HCC such as TOP2A (Wong et al., 2009) , which is a target for topoisomerase inhibitors, but also highlights new markers including the solute carriers SLC2A5/GLUT5, SLC16A3/MCT, SLC7A11 and the melphalan transporter SLC7A5/LAT1
(del Amo et al., 2008) . It is possible that these uptake transporters might facilitate cellular entry
of certain yet unidentified drug species, therefore facilitating therapy.
This article has not been copyedited and formatted. The final version may differ from this version. The HCC samples analyzed were comprised of two groups defined by overall survival rate.
Since previous studies indicated the superiority of TLDAs over high density microarrays (confirmed in this work), we used this technique to investigate the differences in gene expression profiles for patients with good and poor overall survival .
Interestingly, our analysis revealed a novel 45-gene signature that was shown to predict overall survival. In addition to well-established markers, we demonstrated 13-fold and 5-fold overexpression of SLC29A2 and SLC16A3/MCT, respectively, in the poor overall survival group. SLC29A2, a nucleoside uptake transporter, mediates the transport of gemcitabine, cladribine, and zidovudine (AZT) (Baldwin et al., 2004; Huang and Sadee, 2006 The ultimate goal of highlighting MDR-linked gene signatures is to be able to sensitize drugresistant cancers. One strategy is the development of targeted therapy using newly identified biomarkers associated with drug resistance, as indicated above. Another approach highlighted in this work is to utilize a resource published earlier by the Golub group, the Connectivity Map, which allows the identification of compounds that might sensitize MDR cancers with a specific gene signature (Lamb, 2007; Lamb et al., 2006; Zhang and Gant, 2008) . We found three This study provides in vitro-based evidence that, if validated in vivo, suggests that the management of cancers intrinsically resistant to standard chemotherapeutic treatments would improve by changing transcriptional profiles, including genes whose expression is known to be associated with drug resistance. We can also envision applying such a strategy to any cancer highly resistant to standard chemotherapy with the goal of reversing its gene expression profile to that of cancers from patients who respond well to treatment.
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